Sector
PharmaceuticalsOpen
₹127.08Prev. Close
₹126.47Turnover(Lac.)
₹5,626.84Day's High
₹140Day's Low
₹127.0152 Week's High
₹149.652 Week's Low
₹77.35Book Value
₹96.02Face Value
₹1Mkt Cap (₹ Cr.)
1,404.65P/E
13.6EPS
9.3Divi. Yield
0.39Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 10.51 | 10.42 | 10.37 | 10.31 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 977.94 | 926.58 | 841.06 | 745.33 |
Net Worth | 988.45 | 937 | 851.43 | 755.64 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Revenue | 636.35 | 465.51 | 441.95 | 426.59 |
yoy growth (%) | 36.7 | 5.33 | 3.6 | 43.2 |
Raw materials | -343.94 | -253.3 | -236.72 | -225.14 |
As % of sales | 54.04 | 54.41 | 53.56 | 52.77 |
Employee costs | -65.05 | -58.6 | -44.02 | -33.84 |
Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Profit before tax | 123.65 | 91.18 | 121.71 | 120.01 |
Depreciation | -13.84 | -13.76 | -8.83 | -5.74 |
Tax paid | -33.73 | -23.68 | -29.37 | -45.57 |
Working capital | 74.06 | 16.34 | 44.64 | -0.64 |
Other operating items |
Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2019 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 36.7 | 5.33 | 3.6 | 43.2 |
Op profit growth | 19.39 | -8.69 | 7.58 | 5.23 |
EBIT growth | 34.17 | -24.46 | 2.52 | 31.32 |
Net profit growth | 37.27 | -26.89 | 24.04 | 30.55 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 770.24 | 751.59 | 747.45 | 577.21 | 689.31 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 770.24 | 751.59 | 747.45 | 577.21 | 689.31 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 28.74 | 17.79 | 31.49 | 20.22 | 39.19 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,853.75 | 160.77 | 4,47,463.98 | 237.82 | 0.72 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,498.65 | 87.61 | 1,45,516.6 | 430 | 0.55 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,659.7 | 33.69 | 1,33,820.75 | 1,055.94 | 0.78 | 3,752.25 | 346.4 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,451.7 | 77.91 | 1,17,090.09 | 469 | 0.81 | 2,394 | 201.77 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,118.55 | 25.8 | 1,12,713.3 | 1,700.8 | 0.27 | 4,035.4 | 156.19 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Whole-time Director
Vibha G Sharma
Whole-time Director
Shruti Vishal Rao
Chairman & Independent Directo
Subramanian R Vaidya
Non-Exec. & Independent Dir.
Santosh Parab
Company Sec. & Compli. Officer
Aditi Bhatt
Non-Exec. & Independent Dir.
Shilpa Bhatia
Managing Director
Gagan Harsh Sharmma
Independent Director
Nandkumar Kashinath Chodankar
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Bliss GVS Pharma Ltd
Summary
Bliss GVS Pharma Limited was originally incorporated as a Private Limited Company in the name of Bliss Chemicals & Pharmaceuticals India Private Limited in 1984. The status converted into a Public Limited Company and the name of the Company was changed to Bliss Chemicals & Pharmaceuticals India Limited and further to Bliss GVS Pharma Limited on May 12, 2006. The Company, founded in 1984 with the objective of ensuring healthcare access worldwide, is one of the pharmaceutical industries fastest-growing businesses. The Company has a robust portfolio of more than 250 products and is a global leader in the dosage forms for suppositories and pessaries. It has a strong foothold in Sub Saharan Africa. The Company is engaged in manufacturing, marketing, trading and export of pharmaceutical products. The Company has its own manufacturing facility at Palghar which is WHO GMP approved. The business operates five cutting-edge production facilities that adhere to WHO-GMP, EU-MP, ISO 14001 and OHSAS 45001 standards.The company has a dedicated the R&D Centre for development of Suppositories, Semi Solids and Oral Solids with an experienced Team of over 50 Scientists for formulation development and analytical method development and certified by the Department of Scientific & Industrial Research (DSIR), Government of India.The company commenced its business in 1985. In 1994 the company introduced a new pharmaceutical product VAGID. During the financial year ended 31 March 2014, Bliss GVS Pharma
Read More
The Bliss GVS Pharma Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹133.82 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Bliss GVS Pharma Ltd is ₹1404.65 Cr. as of 13 Sep ‘24
The PE and PB ratios of Bliss GVS Pharma Ltd is 13.6 and 1.34 as of 13 Sep ‘24
The 52-week high/low is the highest and lowest price at which a Bliss GVS Pharma Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Bliss GVS Pharma Ltd is ₹77.35 and ₹149.6 as of 13 Sep ‘24
Bliss GVS Pharma Ltd's CAGR for 5 Years at 2.78%, 3 Years at 4.62%, 1 Year at 38.67%, 6 Month at 16.35%, 3 Month at 21.09% and 1 Month at 12.26%.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice